China refines its Hatch-Waxman counterpart as Beijing IP Court highlights nine pharma patent cases

Context: 

• China introduced its pharmaceutical patent-linkage system in 2021 to resolve patent disputes before generic market entry, providing a Chinese counterpart to the patent-linkage mechanism under the U.S. Hatch-Waxman framework. The Beijing Intellectual Property Court has exclusive first-instance jurisdiction over drug patent-linkage litigation nationwide. The Beijing court, the Supreme People’s Court (SPC) and the China National Intellectual Property Administration (CNIPA) have since progressively clarified how the system operates in practice (August 17, 2026 ip fray article, September 16, 2026 ip fray article and October 26, 2026 ip fray article). 
• This continuing clarification aligns with the State Council’s 15th Five-Year IP Plan (2026–2030), which calls for continued improvement of the early-resolution mechanism for drug patent disputes and greater consistency in judicial standards and the application of law (August 4, 2026 ip fray article). It also aligns with the CNIPA’s emphasis on closer coordination between patent validity proceedings and drug patent-linkage disputes in its examination plan for the same period (November 4, 2026 ip fray article).

What’s new: On November 11, 2026, the Beijing Intellectual Property Court reported on five years of adjudication under China’s pharmaceutical patent-linkage system. Between June 2021 and June 2026, it accepted 382 linkage cases and concluded 369; more than 90% of the accepted cases were foreign-related. The court took a further step toward clarifying pharmaceutical patent rules by releasing its first consolidated collection of nine selected cases, covering patentability, validity and patent-linkage disputes (November 11, 2026 Beijing Intellectual Property Court release).

Direct impact: The nine cases give originators and generic manufacturers practical guidance on pharmaceutical patentability, validity and claim scope, as well as the substantive and procedural rules governing patent-linkage disputes. Each case’s principal holding and implications for future disputes are discussed below.

Wider ramifications: China’s growing innovative-drug sector gives domestic companies an increasing stake in effective and predictable patent protection. By distilling rules from decided cases, the court seeks to give both domestic and international companies a more stable basis for research investment, patent strategy and commercialization. The broader objective is to support pharmaceutical innovation while preserving legitimate routes to generic competition and improving access to medicines.